CR5 Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Oculis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.00 |
| 52 Week High | US$12.60 |
| 52 Week Low | US$8.65 |
| Beta | 0.0083 |
| 11 Month Change | 0% |
| 3 Month Change | 3.77% |
| 1 Year Change | 27.17% |
| 33 Year Change | 31.26% |
| 5 Year Change | n/a |
| Change since IPO | 36.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| CR5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.8% |
| 1Y | 27.2% | -18.3% | 8.6% |
Return vs Industry: CR5 exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: CR5 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| CR5 volatility | |
|---|---|
| CR5 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine CR5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Fundamentals Summary
| CR5 fundamental statistics | |
|---|---|
| Market cap | €615.36m |
| Earnings (TTM) | -€74.92m |
| Revenue (TTM) | €934.06k |
658.8x
P/S Ratio-8.2x
P/E RatioIs CR5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CR5 income statement (TTM) | |
|---|---|
| Revenue | CHF 868.00k |
| Cost of Revenue | CHF 48.35m |
| Gross Profit | -CHF 47.48m |
| Other Expenses | CHF 22.14m |
| Earnings | -CHF 69.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | -5,470.16% |
| Net Profit Margin | -8,020.85% |
| Debt/Equity Ratio | 0% |
How did CR5 perform over the long term?
See historical performance and comparison